Boehringer Ingelheim RCV GmbH & Co KG
Boehringer Ingelheim Regional Center Vienna (RCV)
The Austrian subsidiary of the international group, founded in 1948 in a pharmacy in Vienna, was Boehringer Ingelheim’s first affiliated company abroad. From its modest beginnings, it has developed to become a modern high-technology company.
Today, the Boehringer Ingelheim Regional Center Vienna is responsible for the company’s business with prescription medications and veterinary medicines in Austria and more than thirty countries in Central and Eastern Europe and Central Asia, as well as Israel and Switzerland. In addition, all of the clinical research in the region is managed from Vienna. Vienna is the main center of cancer research as well as an important site of the Group’s biopharmaceutical research, development and production. Boehringer Ingelheim also engages in basic research at the Research Institute of Molecular Pathology (IMP) in Vienna. In 2019, the Regional Center Vienna showed an operating performance of EUR 1,495.4 million, net sales of EUR 1,022.5 million and employed 3,780 people throughout the region, there of 2,097 in Austria.